Publications

Beltran H, Rickman DS, Park K, Chae SSuk, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST et al..  2011.  Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.. Cancer Discov. 1(6):487-95.

Svensson MA, Lafargue CJ, MacDonald TY, Pflueger D, Kitabayashi N, Santa-Cruz AM, Garsha KE, Sathyanarayana UG, Riley JP, Yun CS et al..  2011.  Testing mutual exclusivity of ETS rearranged prostate cancer.. Lab Invest. 91(3):404-12.

Svensson MA, Lafargue CJ, MacDonald TY, Pflueger D, Kitabayashi N, Santa-Cruz AM, Garsha KE, Sathyanarayana UG, Riley JP, Yun CS et al..  2011.  Testing mutual exclusivity of ETS rearranged prostate cancer.. Lab Invest. 91(3):404-12.

Park K, Tomlins SA, Mudaliar KM, Chiu Y-L, Esgueva R, Mehra R, Suleman K, Varambally S, Brenner JC, MacDonald T et al..  2010.  Antibody-based detection of ERG rearrangement-positive prostate cancer.. Neoplasia. 12(7):590-8.

Rickman DS, Chen Y-B, Banerjee S, Pan Y, Yu J, Vuong T, Perner S, Lafargue CJ, Mertz KD, Setlur SR et al..  2010.  ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression.. Neoplasia. 12(12):1031-40.

Rickman DS, Chen Y-B, Banerjee S, Pan Y, Yu J, Vuong T, Perner S, Lafargue CJ, Mertz KD, Setlur SR et al..  2010.  ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression.. Neoplasia. 12(12):1031-40.

Perner S, Svensson MA, Hossain RR, Day JR, Groskopf J, Slaughter RC, Jarleborn AR, Hofer MD, Kuefer R, Demichelis F et al..  2010.  ERG rearrangement metastasis patterns in locally advanced prostate cancer.. Urology. 75(4):762-7.

Perner S, Svensson MA, Hossain RR, Day JR, Groskopf J, Slaughter RC, Jarleborn AR, Hofer MD, Kuefer R, Demichelis F et al..  2010.  ERG rearrangement metastasis patterns in locally advanced prostate cancer.. Urology. 75(4):762-7.

Sboner A, Habegger L, Pflueger D, Terry S, Chen DZ, Rozowsky JS, Tewari AK, Kitabayashi N, Moss BJ, Chee MS et al..  2010.  FusionSeq: a modular framework for finding gene fusions by analyzing paired-end RNA-sequencing data.. Genome Biol. 11(10):R104.

Sboner A, Habegger L, Pflueger D, Terry S, Chen DZ, Rozowsky JS, Tewari AK, Kitabayashi N, Moss BJ, Chee MS et al..  2010.  FusionSeq: a modular framework for finding gene fusions by analyzing paired-end RNA-sequencing data.. Genome Biol. 11(10):R104.

Sboner A, Demichelis F, Calza S, Pawitan Y, Setlur SR, Hoshida Y, Perner S, Adami H-O, Fall K, Mucci LA et al..  2010.  Molecular sampling of prostate cancer: a dilemma for predicting disease progression.. BMC Med Genomics. 3:8.

Esgueva R, Perner S, LaFargue CJ, Scheble V, Stephan C, Lein M, Fritzsche FR, Dietel M, Kristiansen G, Rubin MA.  2010.  Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort.. Mod Pathol. 23(4):539-46.

Demichelis F, Setlur SR, Beroukhim R, Perner S, Korbel JO, Lafargue CJ, Pflueger D, Pina C, Hofer MD, Sboner A et al..  2009.  Distinct genomic aberrations associated with ERG rearranged prostate cancer.. Genes Chromosomes Cancer. 48(4):366-80.

Demichelis F, Setlur SR, Beroukhim R, Perner S, Korbel JO, Lafargue CJ, Pflueger D, Pina C, Hofer MD, Sboner A et al..  2009.  Distinct genomic aberrations associated with ERG rearranged prostate cancer.. Genes Chromosomes Cancer. 48(4):366-80.

Tomlins SA, Bjartell A, Chinnaiyan AM, Jenster G, Nam RK, Rubin MA, Schalken JA.  2009.  ETS gene fusions in prostate cancer: from discovery to daily clinical practice.. Eur Urol. 56(2):275-86.

Hofer MD, Kuefer R, Maier C, Herkommer K, Perner S, Demichelis F, Paiss T, Vogel W, Rubin MA, Hoegel J.  2009.  Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer.. Cancer Res. 69(2):640-6.

Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, Ma J, Fiorentino M, Kurth T, Loda M et al..  2009.  Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol. 27(21):3459-64.

Pflueger D, Rickman DS, Sboner A, Perner S, Lafargue CJ, Svensson MA, Moss BJ, Kitabayashi N, Pan Y, de la Taille A et al..  2009.  N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.. Neoplasia. 11(8):804-11.

Pflueger D, Rickman DS, Sboner A, Perner S, Lafargue CJ, Svensson MA, Moss BJ, Kitabayashi N, Pan Y, de la Taille A et al..  2009.  N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.. Neoplasia. 11(8):804-11.

Mosquera J-M, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT et al..  2009.  Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.. Clin Cancer Res. 15(14):4706-11.

Mosquera J-M, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT et al..  2009.  Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.. Clin Cancer Res. 15(14):4706-11.

Rickman DS, Pflueger D, Moss B, VanDoren VE, Chen CX, de la Taille A, Kuefer R, Tewari AK, Setlur SR, Demichelis F et al..  2009.  SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer.. Cancer Res. 69(7):2734-8.

Rickman DS, Pflueger D, Moss B, VanDoren VE, Chen CX, de la Taille A, Kuefer R, Tewari AK, Setlur SR, Demichelis F et al..  2009.  SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer.. Cancer Res. 69(7):2734-8.

Perner S, Wagner PL, Soltermann A, LaFargue C, Tischler V, Weir BA, Weder W, Meyerson M, Giordano TJ, Moch H et al..  2009.  TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival.. J Pathol. 217(1):65-72.

Mertz KD, Demichelis F, Sboner A, Hirsch MS, Dal Cin P, Struckmann K, Storz M, Scherrer S, Schmid DM, Strebel RT et al..  2008.  Association of cytokeratin 7 and 19 expression with genomic stability and favorable prognosis in clear cell renal cell cancer.. Int J Cancer. 123(3):569-76.